CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗实体瘤的障碍与改进策略
英文原题：Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.
查看英文原题
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法通过基因改造患者T细胞使其表达CAR，在血液系统癌症治疗中表现出显著疗效。然而，实体瘤中的应用受到肿瘤浸润不足、免疫抑制性微环境及代谢障碍等因素限制。本综述探讨实体瘤CAR-T 的潜在靶点，并考察增强肿瘤穿透、细胞存活和细胞毒作用的创新策略，包括先进CAR设计、联合疗法及改善代谢竞争环境下CAR-T 功能的方法。随着研究和技术不断进步，CAR-T 疗法有望成为实体瘤治疗的可行选择；未来工作将强调跨学科协作，以充分发挥其潜力。
展开英文摘要原文
CAR-T cell therapy, which genetically modifies a patient s T cells to express chimeric antigen receptors (CARs), has shown remarkable efficacy in treating blood cancers.
However, its application to solid tumors is hindered by challenges such as inadequate tumor infiltration, an immunosuppressive microenvironment, and metabolic obstacles. This review explores potential targets for CAR-T cells in solid tumors and examines innovative strategies to enhance their tumor penetration, survival, and cytotoxicity.
These include advanced CAR designs, combination therapies, and methods to improve CAR-T cell function amidst metabolic competition. As research and technology progress, CAR-T therapy holds promise as a viable option for solid tumor treatment, with future efforts emphasizing interdisciplinary collaboration to unlock its full potential.
论文信息
- 作者
- Luo Z、Hu Q、Ren M、Wang L、Zou Q、Wen X、Chen S、Liu Q
- 第一作者单位
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China.China
- 通讯作者单位
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China. guozifen76@163.com.China
- 文献类型
- 综述
- 期刊
- Discover oncology2026 Feb 10
- 原文标识
- PubMed 41665753 · DOI 10.1007/s12672-026-04473-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →